Celera Genomics & Seattle Genetics Announce Collaboration to Co-Develop Targeted Antibody Therapies for Cancer.
Linked as:
Extract
Celera Genomics & Seattle Genetics Announce Collaboration to Co-Develop Targeted Antibody Therapies for Cancer.
ROCKVILLE, Md. & BOTHELL, Wash. -- Celera Genomics Group (NYSE:CRA), an Applera Corporation business, and Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that they have formed a strategic collaboration to jointly discover and develop antibody-based therapies for cancer. Products developed under the collaboration may include either monoclonal antibodies or antibodies linked to potent cell-killing payloads utilizing Seattle Genetics' antibody-drug-c...
See the full content of this document
Sponsored links
